TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27166718

Group type: EXPERIMENTAL
Intervention: 25 μg of hCG, intravenously
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (normal controls, n=10)
Number of subjects: 14
Study: 25429036

Group type: EXPERIMENTAL
Intervention: Immediate therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Delayed therapy (scaling and root planing, oral hygiene instruction, chlorhexidine rinse)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 473
Study: 23692648

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of sessions concerning sports, parental involvement, individual counselling, lifestyle advice including dietary advice and cognitive behavioural therapy for 18 months.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 104
Study: 20673506

Group type: EXPERIMENTAL
Intervention: BSD2000 deep hyperthermia combined with chemotherapy (paclitaxel: 135 mg/m2 ivdirp 3 h qd d1 + cisplatin: 20 mg/m2 ivdirp qd d1-5)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel and cisplatin)
Number of subjects: 60
Study: 18216572

Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome
Number of subjects: 38

Group type: COMPARATOR
Intervention: IntraLase femtosecond laser
Number of subjects: 38
Study: 16624686

Group type: EXPERIMENTAL
Intervention: Spironolactone prescribed at discharge
Number of subjects: 9165
Study: 14661009

Group type: EXPERIMENTAL
Intervention: Candesartan 4 mg/d
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control (baseline treatment alone)
Number of subjects: 406
Study: 14998239

Group type: EXPERIMENTAL
Intervention: Rare stimulus (short and more intense vibration)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Frequent stimulus (long and less intense vibration)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No stimulus
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rare stimulus
Number of subjects: 8

Group type: COMPARATOR
Intervention: Frequent stimulus
Number of subjects: 8
Study: 10079417

Group type: EXPERIMENTAL
Intervention: High-frequency exercise training (10 sessions per week)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Low-frequency exercise training (2 sessions per week)
Number of subjects: 130
Study: 7484034

Group type: COMPARATOR
Intervention: 0.5% prilocaine with methylparaben (Citanest)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.5% prilocaine without methylparaben
Number of subjects: 200
Study: 2124180

Group type: EXPERIMENTAL
Intervention: Norethisterone enantate 50 mg with estradiol valerate 5 mg (monthly injectable contraceptive)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 6153846

Group type: EXPERIMENTAL
Intervention: Oral tetracycline hydrochloride (Amphocycline)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral tetracycline hydrochloride with 10% ethyl lactate solution applied twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Local application of ethyl lactate solution only
Number of subjects: 15
Study: 27503905

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg/mL three times weekly (GA40)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo during the PC phase, then GA40 during the OL phase (DS group)
Number of subjects: 1041
Study: 25929558

Group type: EXPERIMENTAL
Intervention: Guardian Laryngeal Mask Airway (G‐LMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (P‐LMA)
Number of subjects: 80
Study: 23321934

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 16
Study: 21410839

Group type: EXPERIMENTAL
Intervention: MTZ in situ gel (0.8% metronidazole), applied twice daily for 5 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional vaginal gel product, applied twice daily for 5 days
Number of subjects: 42
Study: 19561037

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 233

Group type: COMPARATOR
Intervention: Dexamethasone (12‐16 mg i.v. on day 1, 8 mg i.v. on day 2, and 4‐8 mg i.v. on day 3)
Number of subjects: 233
Study: 17602038

Group type: EXPERIMENTAL
Intervention: 4.5 mg intrathecal bupivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: 12 mg intrathecal bupivacaine
Number of subjects: 52
Study: 15106360

Group type: EXPERIMENTAL
Intervention: recombinant human follicle stimulating hormone (rhFSH) (Gonal‐F, Serono)
Number of subjects: 20

Group type: COMPARATOR
Intervention: urinary human FSH (uhFSH) (Metrodin, Serono)
Number of subjects: 20
Study: 11528569

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (1 g given weekly)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Benzathine penicillin G (1.2 million U)
Number of subjects: 464
Study: 9771865

Group type: EXPERIMENTAL
Intervention: Breakfast provided every school day for 1 school year
Number of subjects: 814

Group type: COMPARATOR
Intervention: Control group (one-quarter of an orange and same attention as breakfast group)
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Breakfast provided
Number of subjects: 814

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 814
Study: 7837215

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 293
Study: 3277450

Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy with experienced clinicians
Number of subjects: 61

Group type: COMPARATOR
Intervention: Mutual‐help group treatment led by nonclinicians
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (Brief dynamic psychotherapy and Mutual-help group treatment)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Subgroup who completed the majority of sessions
Number of subjects: 61
Study: 30738706

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 4775

Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 4775

Group type: EXPERIMENTAL
Intervention: Combined risks of CEA and CAS
Number of subjects: 4775
Study: 28363636

Group type: EXPERIMENTAL
Intervention: DSM265 (150 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Mefloquine (10 mg/kg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DSM265
Number of subjects: 82
Study: 26431662

Group type: EXPERIMENTAL
Intervention: 10mg adefovir dipivoxil capsules once daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 10mg adefovir dipivoxil capsules once daily + 5 million U Recombinant Human Interferon α‐2b every other day
Number of subjects: 102

Group type: COMPARATOR
Intervention: 10mg adefovir dipivoxil capsules once daily (control group)
Number of subjects: 102
Study: 23422375

Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline administration (Control)
Number of subjects: 28
Study: 20700581

Group type: EXPERIMENTAL
Intervention: Weight (50-90 kg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Weight changes up to 5 kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Spine BMD
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Femoral neck BMD
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Total hip BMD
Number of subjects: 64
Study: 19648681

Group type: EXPERIMENTAL
Intervention: CPT before BiPAP treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: BiPAP treatment after conventional anti-infection, phlegm treatment and support treatment
Number of subjects: 90
Study: 17455407

Group type: EXPERIMENTAL
Intervention: 2 microg/Kg fentanyl IV
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.2 microg/Kg sufentanil IV
Number of subjects: 141

Group type: COMPARATOR
Intervention: 2 ml isotonic normal saline (Control)
Number of subjects: 141
Study: 15155117

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study: 12414877

Group type: EXPERIMENTAL
Intervention: QUICKI (quantitative insulin sensitivity check index)
Number of subjects: 208

Group type: COMPARATOR
Intervention: QUICKI tertiles
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Insulin resistance measured by HOMA
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Maximal IMT of the CCA
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Severe CCA atherosclerosis
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure and HDL cholesterol
Number of subjects: 208
Study: 9809097

Group type: EXPERIMENTAL
Intervention: 6% low molecular weight HES (MW 120,000/0.7) at 20 vol.%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10% low molecular weight HES (MW 200,000/0.5) at 20 vol.%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6% high molecular weight HES (MW 400,000/0.7) at 20 vol.%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ringer's acetate at 20 vol.%
Number of subjects: 10

Group type: COMPARATOR
Intervention: 4% albumin at 20 vol.%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All solutions at 50 vol.%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HES 400 at 50 vol.%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HES 200 at 50 vol.%
Number of subjects: 10
Study: 7635125

Group type: EXPERIMENTAL
Intervention: Short system response times (SRTs of 0.5s)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long system response times (SRTs of 4.5s)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (non-incentive)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 40
Study: 2676967

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) at an average maximal daily dose of 4.6 +/- 0.2 mg/kg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 365323

Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg three times a day)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 31510992

Group type: EXPERIMENTAL
Intervention: Pre-scoring system for NLBP risk assessment
Number of subjects: 1439
Study: 28675067

Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (NeoTMZ) 200 mg/m2 days 1-5 every 28 days followed by RT 60 Gy in 30 fractions
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard radiotherapy (RT) only
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (NeoTMZ) for AA patients
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard radiotherapy (RT) for AA patients
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (NeoTMZ) for GBM patients
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard radiotherapy (RT) for GBM patients
Number of subjects: 144
Study: 24844580

Group type: EXPERIMENTAL
Intervention: NIM‐Response 3.0 system
Number of subjects: 252

Group type: COMPARATOR
Intervention: Conventional technique using the Vari‐Stim 3
Number of subjects: 252
Study: 23742808

Group type: EXPERIMENTAL
Intervention: Revised version of Change Your Drinking
Number of subjects: 595

Group type: COMPARATOR
Intervention: Original version of Change Your Drinking
Number of subjects: 595
Study: 22019520

Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy
Number of subjects: 148
Study: 19358086

Group type: EXPERIMENTAL
Intervention: Training of power and balance
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (different hospital)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Patients treated in the year before
Number of subjects: 159
Study: 16948115

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg plus MTX
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg plus MTX
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 299
Study: 15361763

Group type: EXPERIMENTAL
Intervention: L-arginine (10 micromol/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: N-monomethyl-L-arginine (L-NMMA; 4 micromol/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acetylcholine (9 and 37 microg/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium nitroprusside (200 and 800 ng/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoproterenol (50 and 200 ng/min)
Number of subjects: 40
Study: 12575372

Group type: EXPERIMENTAL
Intervention: Tracheitis Plaster (TP) applied on acupoints Dingchuan, Dashu, Fengmen, Feishu and Xinshu at back along both sides of thoracic vertebrae 1‐6, treatment duration: 20 times.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intramuscular injection of Siqikang, treatment duration: 20 times.
Number of subjects: 84
Study: 9051545

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Endotracheal Intubation
Number of subjects: 202
Study: 8326288

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3549096

Group type: EXPERIMENTAL
Intervention: Nasal spray (200 units daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal spray (400 units daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Suppository (300 units)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Parenteral route
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31509844

Group type: EXPERIMENTAL
Intervention: Calcipotriol-betamethasone ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 29265563

Group type: EXPERIMENTAL
Intervention: Digital intervention to improve physical activity levels
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Digital intervention
Number of subjects: 1564
Study: 27473888

Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg every 4 weeks for up to six injections)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Radium-223 plus abiraterone or enzalutamide
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Radium-223 plus denosumab
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Any-grade treatment-emergent adverse events
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Grade 3 or worse treatment-related adverse events
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 696
Study: 23887199

Group type: EXPERIMENTAL
Intervention: Low-volume group (1 ml·kg·h of balanced Ringer's solution until the end of cystectomy and then 3 ml·kg·h until the end of surgery combined with preemptive norepinephrine infusion at an initial rate of 2 µg·kg·h)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (6 ml·kg·h of balanced Ringer's solution throughout surgery)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Low-volume group
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study: 23327960

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide combined with transcatheter arterial chemoembolization (TACE) - 10 mg arsenic trioxide by intravenous infusion for 5 hours per day, 3 days after TACE, repeated every 2 weeks for 3-4 cycles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received periodic TACE alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide combined with TACE
Number of subjects: 60
Study: 20735160

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 100
Study: 18358541

Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C‐CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute phase cognitive therapy (A‐CT)
Number of subjects: 0
Study: 15129392

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B) 10000 U
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11694172

Group type: EXPERIMENTAL
Intervention: 15% body weight support (BWS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0% body weight support (harness in place but no use of external support)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No body weight support (standard test)
Number of subjects: 15
Study: 9504514

Group type: EXPERIMENTAL
Intervention: Autologous bone-marrow transplant (BMT) after preparation with cyclophosphamide and total-body irradiation
Number of subjects: 381

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 381
Study: 8061425

Group type: EXPERIMENTAL
Intervention: BMS 180549 (superparamagnetic iron oxide contrast agent)
Number of subjects: 41
Study: 2661065

Group type: EXPERIMENTAL
Intervention: Low dose cyclosporin A (CyA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: High dose cyclosporin A (CyA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low dose cyclosporin A (CyA) with NSAIDs
Number of subjects: 39
Study: 780406

Group type: EXPERIMENTAL
Intervention: Specific injection therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study: 31236286

Group type: EXPERIMENTAL
Intervention: Hyoscine (1 week at 0.6 mg daily, 3 weeks at 0.9 mg daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (1 week at 2 mg daily, 3 weeks at 3 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29231337

Group type: EXPERIMENTAL
Intervention: Balance acupuncture at Toutongxue point, treatment for 4 weeks, once a day, 5 times a week.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham acupuncture at a control point (3, 4 metatarsal combination), treatment for 4 weeks, once a day, 5 times a week.
Number of subjects: 40
Study: 25691764

Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 10

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 10
Study: 23322818

Group type: EXPERIMENTAL
Intervention: MHT (Menopausal Hormone Treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 21644837

Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam
Number of subjects: 90

Group type: COMPARATOR
Intervention: 400 mg ibuprofen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19084935

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 16404492

Group type: EXPERIMENTAL
Intervention: High-impact exercise (acceleration levels exceeding 3.9 g)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-impact exercise (acceleration levels exceeding 5.4 g)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physical activity at levels of 1.1-2.4 g
Number of subjects: 120
Study: 12622303

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 464
Study: 11244343

Group type: EXPERIMENTAL
Intervention: Hypotonic artificial tears, administered up to 6 times a day
Number of subjects: 158

Group type: COMPARATOR
Intervention: Isotonic artificial tears, administered up to 6 times a day
Number of subjects: 158
Study: 9256118

Group type: EXPERIMENTAL
Intervention: MOPP-ABVD with low-dose total-nodal irradiation (TNI)
Number of subjects: 179

Group type: COMPARATOR
Intervention: MOPP-ABVD only (chemotherapy-only group)
Number of subjects: 179
Study: 8509099

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus subcutaneously administered interferon alpha‐2a
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cryotherapy plus placebo
Number of subjects: 97
Study: 3512421

Group type: EXPERIMENTAL
Intervention: Health education and counselling reinforced by a doctor
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (standard health education and counselling)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 29415656

Group type: EXPERIMENTAL
Intervention: Beach chair method (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control method (n=30)
Number of subjects: 60
Study: 26654786

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise)
Number of subjects: 0
Study: 24286534

Group type: EXPERIMENTAL
Intervention: 150 mg Polaprezinc (PZ) enema
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (non-PZ group)
Number of subjects: 28
Study: 22331335

Group type: EXPERIMENTAL
Intervention: Primary care-based, multicomponent lifestyle intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 208
Study: 20730637

Group type: EXPERIMENTAL
Intervention: Any condom use
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Inconsistent condom use
Number of subjects: 1204
Study: 17991903

Group type: EXPERIMENTAL
Intervention: Competency-based counseling training program
Number of subjects: 106
Study: 16026492

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1432
Study: 12848770

Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol (FP/SM) 125 microg/SM 25 microg, 1 puff twice daily for 3 weeks
Number of subjects: 14